Fig. 1From: Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseasesProbability of golimumab retention after discontinuation of non-TNFi biologicals or tsDMARDs by line of therapyBack to article page